Última actualización 24 de agosto de 2026
Key finding
UACR decreased significantly in participants treated with vicadrostat.
The study investigated the effects of Vicadrostat and Vicadrostat plus Empagliflozin on urinary extracellular vesicle microRNAs in chronic kidney disease. Significant decreases in urinary albumin-to-creatinine ratio were observed with both treatments.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study investigated the effects of Vicadrostat and Vicadrostat plus Empagliflozin on urinary extracellular vesicle microRNAs in chronic kidney disease. Significant decreases in urinary albumin-to-creatinine ratio were observed with both treatments.
These findings are clinically significant as they suggest that Vicadrostat may effectively reduce urinary markers of kidney damage, potentially benefiting patients with chronic kidney disease. This could lead to improved management strategies for preserving kidney function and preventing disease progression.
Unclear effectiveness for some outcomes. Limited generalizability due to specific participant characteristics. Small sample size may affect the robustness of findings.
Published in
Publication details and source links for this paper.
Denis D, Isabella G, Ileana D, et al. Vicadrostat Plus Empagliflozin Alters Urinary Extracellular Vesicle MicroRNAs in Chronic Kidney Disease. International Journal of Molecular Sciences. 2025;26(22):10810. doi:10.3390/ijms262210810
UACR decreased significantly by -30 mg/g (p=0.001) in participants treated with Vicadrostat.
Participants treated with Vicadrostat plus Empagliflozin also showed a significant decrease in UACR.
No significant change in estimated glomerular filtration rate (eGFR) was observed.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Vicadrostat, Vicadrostat plus Empagliflozin and Estimated glomerular filtration rate, Hypokalaemia incidence, Systolic blood pressure, and 4 more.
This study contributes evidence to
Primary intervention
Vicadrostat
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
10
Evidence pairs
103
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Core evidence
The primary outcomes reported in this study.
Vicadrostat → Estimated glomerular filtration rate
Vicadrostat → Estimated glomerular filtration rate
Vicadrostat → UACR reduction of at least 30%
Vicadrostat → UACR reduction of at least 30%
Vicadrostat → Urinary albumin-to-creatinine ratio
Vicadrostat → Urinary albumin-to-creatinine ratio
Vicadrostat plus Empagliflozin → Blood pressure reduction
Vicadrostat plus Empagliflozin → Blood pressure reduction
Vicadrostat plus Empagliflozin → Estimated glomerular filtration rate
Vicadrostat plus Empagliflozin → Estimated glomerular filtration rate
Vicadrostat plus Empagliflozin → Serum potassium
Vicadrostat plus Empagliflozin → Serum potassium
Vicadrostat plus Empagliflozin → UACR reduction of at least 30%
Vicadrostat plus Empagliflozin → UACR reduction of at least 30%
Vicadrostat plus Empagliflozin → Urinary albumin-to-creatinine ratio
Vicadrostat plus Empagliflozin → Urinary albumin-to-creatinine ratio
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Vicadrostat and Kidney Function, Vicadrostat and Hypokalaemia incidence.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
All studies measuring Hypokalaemia incidence
Measures Hypokalaemia incidence as a key outcome.
All studies measuring Kidney Function
Measures Kidney Function as a key outcome.
All studies on Vicadrostat
Contributes to Vicadrostat evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Vicadrostat appears to improve UACR reduction of at least 30%.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
UACR reduction of at least 30%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Vicadrostat appears to improve Urinary albumin-to-creatinine ratio.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Urinary albumin-to-creatinine ratio
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Vicadrostat plus Empagliflozin appears to improve UACR reduction of at least 30%.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
UACR reduction of at least 30%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Vicadrostat plus Empagliflozin appears to improve Urinary albumin-to-creatinine ratio.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Urinary albumin-to-creatinine ratio
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
